- Supported exchanges /
- NASDAQ /
- HUMAW.NASDAQ
Humacyte Inc (HUMAW NASDAQ) stock market data APIs
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Humacyte Inc Financial Data Overview
1.535 | |
2.08 | |
- | |
2.2 | |
1.31 | |
0.3475-3.47 | |
0 | |
0 | |
0 | |
-0.7181 | |
1.452 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Humacyte Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -99 648 000
- Earnings Per Share -3.158
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Humacyte Inc Earnings via APIs
- Latest Release 2021-09-30
- EPS/Forecast 0
Get Humacyte Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: